Skip to main content

Table 1 Clinical characteristics of patients and tumor staging

From: Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control

Age (years)   
  Median (range) 72 (53–77)
Follow-up (mos)   
  Median (range) 71 (32.8-93.6)
Stage (N /%)   
  T1c 1 (2.5%)
T2a 11 (28%)
T2b 15 (38.5%)
T2c 12 (31%)
Gleason score   
  <=6 13 (33.3%)
7 (3 + 4) 20 (51.3%)
7 (4 + 3) 6 (15.4%)
% Biopsy core   
  0-24% 12 (31%)
25-49% 16 (41%)
50-74% 10 (26%)
75-100% 1 (2%)
iPSA   
  <10 37 (95%)
  10–19.9 2 (5%)